Allergists are well trained in the diagnosis and medical management of various allergic conditions. However, allergists can also play a central role in addressing other important aspects of these conditions that patients face in their daily lives. Allergists can lead the charge in educating other medical professionals and promoting quality care while also generating interest in our specialty among the next generation of physicians.

Moderator: Luz S. Fonacier, MD, FACAAI

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

This session will update the participant on the current state-of-the-art regarding spontaneous urticaria and physical or inducible urticarias. A comprehensive overview of the pathophysiology, differential diagnosis and treatment strategies will be discussed. The participant will gain an understanding of the various treatment guidelines referred to in the U.S. and Europe. At the end of this session, the participant will have an understanding of the approach to diagnosis and treatment of patients with spontaneous and inducible urticarias.

Moderators: Sandra M. Gawchik, DO, FACAAI, and Jonathan S. Tam, MD, FACAAI

MOC/CME

Our changing climate has impacted not only our temperatures, but the onset and duration of pollen season as well. It is important for allergists to understand the impact that climate change is having on our patients and to anticipate changes to how we provide care. Natural disasters create many challenges and are extremely disruptive to people’s lives. An often-neglected aspect of natural disasters includes the impact that flooding, fires and severe weather can have on the health of people with asthma and allergic conditions. Allergists who care for patients in natural disaster-prone areas can help them prepare for when those disasters strike.

Moderators: William K. Dolen, MD, FACAAI, and Meagan W. Shepherd, MD, FACAAI

The CAP Review is a literature-style review covering most of the articles chosen by the ABAI for the current six-month cycle of the Continuous Assessment Program (CAP). Each presenter will focus on key aspects of the study design, results and implications for practice. The goal of this session is to help prepare attendees for the second cycle of ABAI CAP program.

Moderator: Lisa J. Kobrynski, MD, MPH, FACAAI

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

MOC/CME

This session will provide a foundation for exploring newer medical, surgical and biologic therapies for chronic rhinosinusitis (CRS) with and without nasal polyps. Etiology, diagnosis and management will be reviewed.

Moderators: Alan B. Goldsobel, MD, FACAAI, and Puneet Shroff, MD, FACAAI

Common issues in managing the care of patients with primary immunodeficiencies will be addressed.

Moderators: Mary Beth Fasano, MD, MSPH, FACAAI, and S. Shahzad Mustafa, MD, FACAAI